



CASE PC/4-32405A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 70606411945  
Express Mail Label Number

July 9, 2008  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
SUTTON ET AL.  
APPLICATION NO: 10/507,255  
FILED: 09/28/04  
FOR: SALTS OF NATEGLINIDE

Art Unit: 1756  
Examiner: Lao, Marialouisa

MS: After Final  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

NOTICE OF APPEAL  
PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Notice of Appeal has a shortened statutory time set to expire on April 30, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

  
Jennifer C. Chapman  
Attorney for Applicants  
Reg. No. 47,487  
Phone No. (862) 778-1202

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080

Date: July 9, 2008

07/11/2008 HGBREH1 00000047 190134 10507255  
02 FC:1253 1050.00 DA



CASE PC/4-32405A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 70606411945</u> Express Mail Label Number	<u>July 9, 2008</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1756

SUTTON ET AL.

Examiner: Lao, Marialouisa

APPLICATION NO: 10/507,255

FILED: 09/28/04

FOR: SALTS OF NATEGLINIDE

MS: After Final  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

NOTICE OF APPEAL  
PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Notice of Appeal has a shortened statutory time set to expire on April 30, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080

Date: July 9, 2008

Jennifer C. Chapman  
Jennifer C. Chapman  
Attorney for Applicants  
Reg. No. 47,487  
Phone No. (862) 778-1202